Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says
By Gina Kim · March 27, 2026, 5:38 PM EDT
Vistagen Therapeutics' current and former top brass have been hit with a derivative shareholder suit in California federal court alleging they overstated its clinical trial for a novel, anti-anxiety drug while...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login